Miami Researcher's Nanoparticle Could Protect Diabetes Patients

Marlene Redlich came to the University of Miami for one year to test whether lab work was right for her. Three years later, she's creating technology that could transform how we treat type 1 diabetes.

The doctoral student has developed a lipid nanoparticle that targets the exact cells destroyed by type 1 diabetes. These microscopic delivery vehicles could protect insulin-producing beta cells in the pancreas before the immune system attacks them.

"We're focusing on the Fas/Fas ligand pathway, which is one of the mechanisms the immune system uses to kill beta cells," Redlich explains. By interrupting that process, patients might never need islet transplantation at all.

Redlich's journey to this breakthrough started in Germany, where both her parents worked as physicians. She loved medicine but discovered her true passion in the lab during undergraduate biochemistry studies.

After college, she specifically applied to Miami because she'd fallen in love with the campus during a high school exchange program years earlier. What she thought would be a one-year research position turned into something bigger when her mentor, Dr. Paolo Serafini, encouraged her to pursue a PhD.

The decision meant five more years away from family in Germany. "That wasn't an easy decision," she admits. But the supportive community at Miller School of Medicine made Miami feel like a second home.

The Ripple Effect

Redlich's research represents more than one student's achievement. It's part of a broader shift toward preventing autoimmune attacks rather than just managing their aftermath.

The small, tight-knit department at Miller School fosters collaboration across disciplines. Redlich regularly discusses her work with friends studying neuroscience and microbiology, often at happy hour. "Sometimes someone outside your field asks a simple question that completely changes the way you think," she says.

She also values conversations with medical students who bring patient perspectives to research discussions. Those interactions remind her why long lab hours matter.

Now preparing her first first-author publication, Redlich thinks about how her work will become part of the permanent scientific record. Other researchers might build on her ideas or discover something entirely new because of her findings.

She recently served as a MedCanes Student Ambassador, sharing her PhD experience on social media. "Representation matters," she says. "When I was younger, I didn't really have examples of people doing what I'm doing."

Her nanoparticles are already moving toward potential clinical applications, bringing hope to millions living with type 1 diabetes worldwide.